Cargando…

Applying Microfluidics for the Production of the Cationic Liposome-Based Vaccine Adjuvant CAF09b

Subunit vaccines require particulate adjuvants to induce the desired immune responses. Pre-clinical manufacturing methods of adjuvants are often batch dependent, which complicates scale-up for large-scale good manufacturing practice (GMP) production. The cationic liposomal adjuvant CAF09b, composed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmidt, Signe Tandrup, Christensen, Dennis, Perrie, Yvonne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767004/ https://www.ncbi.nlm.nih.gov/pubmed/33352684 http://dx.doi.org/10.3390/pharmaceutics12121237

Ejemplares similares

The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8(+) T-cell responses: The immunological consequences of the biodistribution profile
por: Schmidt, Signe Tandrup, et al.
Publicado: (2016)

A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease
por: Zimmermann, Julie, et al.
Publicado: (2022)

Adsorption of protein antigen to the cationic liposome adjuvant CAF®01 is required for induction of Th1 and Th17 responses but not for antibody induction
por: Wørzner, Katharina, et al.
Publicado: (2021)

The Impact of Solvent Selection: Strategies to Guide the Manufacturing of Liposomes Using Microfluidics
por: Webb, Cameron, et al.
Publicado: (2019)

Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators
por: Tandrup Schmidt, Signe, et al.
Publicado: (2016)

Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements
por: Agger, Else Marie, et al.
Publicado: (2008)

Robust antibody and CD8(+) T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection
por: Espinosa, Diego A., et al.
Publicado: (2017)

Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma
por: Mørk, Sofie Kirial, et al.
Publicado: (2022)

Small Cationic DDA:TDB Liposomes as Protein Vaccine Adjuvants Obviate the Need for TLR Agonists in Inducing Cellular and Humoral Responses
por: Milicic, Anita, et al.
Publicado: (2012)

Application of Pharmacokinetics Modelling to Predict Human Exposure of a Cationic Liposomal Subunit Antigen Vaccine System
por: Badhan, Raj K. S., et al.
Publicado: (2017)

Investigating Prime-Pull Vaccination through a Combination of Parenteral Vaccination and Intranasal Boosting
por: Roces, Carla B., et al.
Publicado: (2019)

Translating the fabrication of protein-loaded poly(lactic-co-glycolic acid) nanoparticles from bench to scale-independent production using microfluidics
por: Roces, Carla B., et al.
Publicado: (2020)

Synthesis of protein conjugates adsorbed on cationic liposomes surface
por: Chatzikleanthous, Despo, et al.
Publicado: (2020)

Targeting the Mincle and TLR3 receptor using the dual agonist cationic adjuvant formulation 9 (CAF09) induces humoral and polyfunctional memory T cell responses in calves
por: Thakur, Aneesh, et al.
Publicado: (2018)

Radiolabelling of Antigen and Liposomes for Vaccine Biodistribution Studies
por: Henriksen-Lacey, Malou, et al.
Publicado: (2010)

Point of use production of liposomal solubilised products
por: Khadke, Swapnil, et al.
Publicado: (2018)

Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C)
por: Schmidt, Signe Tandrup, et al.
Publicado: (2018)

Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate
por: Sisteré-Oró, Marta, et al.
Publicado: (2020)

First in man study: Bcl-Xl_42-CAF(®)09b vaccines in patients with locally advanced prostate cancer
por: Mørk, Sofie Kirial, et al.
Publicado: (2023)

Therapeutic Vaccination with Cationic Liposomes Formulated with Dioctadecyldimethylammonium and Trehalose Dibehenate (CAF01) and Peptide P10 Is Protective in Mice Infected with Paracoccidioides brasiliensis
por: de Araújo, Marcelo Valdemir, et al.
Publicado: (2020)

Seasonal Influenza Split Vaccines Confer Partial Cross-Protection against Heterologous Influenza Virus in Ferrets When Combined with the CAF01 Adjuvant
por: Christensen, Dennis, et al.
Publicado: (2018)

Development of a rapid in vitro pre-screen for distinguishing effective liposome-adjuvant delivery systems
por: Feather, Laura A. J., et al.
Publicado: (2022)

Syringe Free Vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles Provides Strong and Prolonged Protection Against Tuberculosis
por: Christensen, Dennis, et al.
Publicado: (2010)

The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency
por: Anderluzzi, Giulia, et al.
Publicado: (2022)

Immunomic Discovery of Adjuvants, Delivery Systems, and Candidate Subunit Vaccines: A Brief Introduction
por: Flower, Darren R., et al.
Publicado: (2012)

Liposome production by microfluidics: potential and limiting factors
por: Carugo, Dario, et al.
Publicado: (2016)

Adjuvant Effect of Cationic Liposomes for Subunit Influenza Vaccine: Influence of Antigen Loading Method, Cholesterol and Immune Modulators
por: Barnier-Quer, Christophe, et al.
Publicado: (2013)

Liposomes as Adjuvants and Vaccine Delivery Systems
por: Tretiakova, D. S., et al.
Publicado: (2022)

Preparation, characterization, and efficient transfection of cationic liposomes and nanomagnetic cationic liposomes
por: Samadikhah, Hamid Reza, et al.
Publicado: (2011)

Immune responses following neonatal vaccination with conserved F4 fragment of VtaA proteins from virulent Glaesserella parasuis adjuvanted with CAF®01 or CDA
por: López-Serrano, Sergi, et al.
Publicado: (2023)

Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis
por: Ravindran, Rajesh, et al.
Publicado: (2010)

Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice
por: Wørzner, Katharina, et al.
Publicado: (2021)

Liposomal delivery system/adjuvant for tuberculosis vaccine
por: Moradi, Melika, et al.
Publicado: (2023)

Evaluation of novel cationic gene based liposomes with cyclodextrin prepared by thin film hydration and microfluidic systems
por: Elsana, Hassan, et al.
Publicado: (2019)

CAF01 Potentiates Immune Responses and Efficacy of an Inactivated Influenza Vaccine in Ferrets
por: Martel, Cyril Jean-Marie, et al.
Publicado: (2011)

Injection Vaccines Formulated with Nucleotide, Liposomal or Mineral Oil Adjuvants Induce Distinct Differences in Immunogenicity in Rainbow Trout
por: Rømer Villumsen, Kasper, et al.
Publicado: (2020)

Immunogenicity and protection effects of cationic liposome containing imiquimod adjuvant on leishmaniasis in BALB/c mice
por: Mehravaran, Ahmad, et al.
Publicado: (2019)

Comparative Analysis of Protein Quantification Methods for the Rapid Determination of Protein Loading in Liposomal Formulations
por: Hussain, Maryam T., et al.
Publicado: (2019)

Anti-RSV Peptide-Loaded Liposomes for the Inhibition of Respiratory Syncytial Virus †
por: Joshi, Sameer, et al.
Publicado: (2018)

CAF08 adjuvant enables single dose protection against respiratory syncytial virus infection in murine newborns
por: van Haren, Simon D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i9rik702st1lfa9af59tpcuacs